Biocon initiates 'Ek Prayaas' nationwide awareness program on Hepatitis C

Image
ANI New Delhi
Last Updated : Jul 28 2016 | 3:13 PM IST

Biocon branded formulations business announced the launch of a new patient support program 'Ek Prayaas' through a nationwide awareness drive for Hepatitis C on the occasion of 'World Hepatitis Day' on July 28th.

Biocon's Virology Division set up in April 2015 is driven with a mission of saving lives with a prime focus on HCV. The 'Ek Prayaas' program in collaboration with healthcare professionals will organize a nationwide HCV awareness campaign across tier I and tier II cities.

The program is aimed to educate the common man about the causes and effects of Hepatitis C. According to WHO July, 2016 data, 130-150 million people globally have chronic Hepatitis C infection. It is estimated that about 1.5 crore people in India are infected by Hepatitis C.

The Biocon Virology division though in its infancy is extensively engaged with Gastroenterologists, Hepatologists, Blood Banks and Deaddiction Centers to create awareness about HCV, updating HCPs on the recommended HCV management approaches and paving the way towards HCV eradication.

"Hepatitis C (HCV) is a neglected disease, with very little public awareness on disease and its implications, if left untreated. With the advent of advanced therapies, Hep C is curable if diagnosed and treated on time. Through 'Ek Prayaas', we aim to increase public awareness on Hep C , enabling early diagnosis and treatment to combat HCV and save several innocent lives. Together with our partners, we hope to eradicate HCV in India," said Senior Director and Business Head Virology Division Biocon, Prakash S Kayal.

Biocon has introduced several lifesaving therapies in this segment with a clear focus on being highly scientific, patient-centric and access-oriented.

Hepatitis-C is a viral disease that causes liver inflammation leading to diminished liver function or liver failure. It is referred to as a silent epidemic as most people infected with HCV have no symptoms of the disease until liver damage becomes apparent, which may take decades.

Chronic HCV infection could lead to scarring and poor liver function

(cirrhosis) over many years, resulting in complications such as bleeding, jaundice, fluid accumulation in the abdomen, infections, and liver cancer.

Hepatitis C is a silent killer disease, it does not cause any obvious symptoms, and people may have it and not even know, HCV virus proliferates in liver cells and over a period of time cause fibrosis, cirrhosis, hepatocellular carcinoma, which is a leading cause of liver transplant or death.

Building awareness about this asymptomatic disease leading to timely diagnosis is imperative for HCV eradication.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 28 2016 | 3:13 PM IST

Next Story